Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (“NASH”), a liver disease with high unmet medical need. In March 2024, the Company announced that Rezdiffra™ (resmetirom) has been granted accelerated approval by the U.S. Food and Drug Administration in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis. Rezdiffra is a once-daily, oral THR-β agonist designed to target key underlying causes of NASH.